Article 55 of Regulation (EU) 2017/745 establishes the scrutiny mechanism for certain Class III implantable devices and certain Class IIb active devices intended to administer or remove a medicinal product. Where an Article 54 clinical evaluation consultation has been carried out, the Notified Body notifies the competent authorities of certificates issued following that consultation, transmits the clinical evaluation assessment report together with the expert panel's scientific opinion, and makes the summary of safety and clinical performance publicly available via Eudamed. Article 55 does not give the expert panel or the competent authorities a veto over the certificate, but it places the certification decision, the clinical evidence, and the expert panel's views into a visible, cross-authority record. For a startup, Article 55 is the reason the file has to be built to be read by strangers.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • Article 55 of Regulation (EU) 2017/745 establishes a scrutiny mechanism in connection with the Article 54 clinical evaluation consultation for certain Class III implantable and Class IIb active devices.
  • The Notified Body notifies the competent authorities of certificates issued after the Article 54 consultation and transmits the CEAR together with the expert panel's scientific opinion.
  • The summary of safety and clinical performance (SSCP) is made publicly available through Eudamed under Article 32.
  • Article 55 is distinct from Article 54: Article 54 is the consultation with an expert panel, Article 55 is the scrutiny, notification, and publication mechanism around it.
  • Article 55 does not give competent authorities or the expert panel a veto over the certificate, but it makes the certificate, CEAR, and expert views visible across the Union.
  • For founders, Article 55 is why the file must be built to be read by people who do not know the device — the discipline is baked into the CER and SSCP during the Article 54 stage.

Why Article 55 exists

Article 54 places an independent expert panel on the clinical evaluation of certain Class III implantable and Class IIb active devices before the certificate is issued. Article 55 is what happens around that consultation to make it visible to the rest of the regulatory system.

The Regulation's logic is simple. If a device warrants an expert panel opinion before certification, the certification decision, the clinical evaluation assessment report (CEAR), the panel's opinion, and a plain-language summary of the clinical evidence should not live only in a bilateral file between one manufacturer and one Notified Body. They should be visible to competent authorities across the Union, and the core safety and performance summary should be visible to the public.

For a startup running a Class III implantable project, Article 55 is the reason the file has to be built to read well to strangers. The Notified Body knows your device. The expert panel does not. The competent authorities across 27 member states do not. The clinicians who read the public summary do not.

For the consultation that Article 55 sits around, see Notified Body opinion under MDR Article 54. For framing, see Class III medical devices under MDR. For the full route, see the conformity assessment procedure for Class III devices.

What Article 55 requires and how it relates to Article 54

Article 54 and Article 55 are often collapsed into one concept — "the scrutiny procedure" — and the collapse causes confusion. The two Articles are distinct and do different work.

Article 54 establishes the clinical evaluation consultation procedure (CECP). The Notified Body sends its CEAR via the Commission to an independent expert panel under Article 106, which issues a scientific opinion. The Notified Body must give due consideration to the opinion and document how it was taken into account. Article 54 is the consultation itself.

Article 55 is the scrutiny, notification, and publication mechanism that sits around Article 54. Where a Notified Body has carried out the Article 54 consultation, it notifies the competent authorities of certificates issued in connection with that procedure. It transmits the CEAR together with the expert panel's scientific opinion so the national authorities see both the Notified Body's assessment and the panel's views on the same clinical evidence. The summary of safety and clinical performance (SSCP) is made publicly available through Eudamed in accordance with Article 32, so a clinician or a competent authority anywhere in the Union can read a plain-language account of what the device is, what clinical evidence supports it, and what is known about its benefit-risk.

The Notified Body remains the decision-maker on whether to issue the certificate. The expert panel's opinion is not a veto, but Article 55 ensures that the opinion and the Notified Body's handling of it travel to the competent authorities — the certificate decision is not a private judgment, it is a reasoned decision visible to people who were not in the room.

A Class III implantable project that is in scope of Article 54 is also in scope of Article 55. The exact obligations and information flow are in Article 55 itself, read together with Article 54, Annex IX Section 5.1, and Article 32 — the founder building a project plan on these provisions must read the consolidated text.

Which devices are in scope, and the timeline that follows

Three conditions together put a device into the Article 55 scrutiny loop. The device falls within Article 54 — certain implantable Class III devices (with the exceptions listed there) and certain Class IIb active devices intended to administer or remove a medicinal product that Article 54 captures. The Article 54 consultation actually runs — if it does not, Article 55 does not engage in the same way. The certificate is issued — Article 55 is about what happens when a Notified Body issues a certificate following the Article 54 process.

Article 55 does not itself add a separate multi-month review cycle. The honest order of magnitude for the Article 54 consultation is several weeks to several months of calendar time on top of the ordinary Annex IX per-device review. Article 55 runs alongside and after — the notification to competent authorities and the SSCP publication are operational steps, not a separate panel review cycle.

Two implications follow. The SSCP is not a post-hoc document written after the certificate lands — it is written during the clinical evaluation and refined through the Article 54 consultation. And the cross-authority visibility of the CEAR and expert panel opinion means a clinical evaluation built on weak evidence does not quietly disappear after certification; the reasoning persists in a record that multiple authorities can read.

A worked example: a Class III implantable startup

Consider a startup with a novel Class III implantable neurostimulation device. No Article 54 exception applies. The conformity assessment runs under Annex IX, the Notified Body prepares its CEAR, and the Article 54 consultation is triggered. The CEAR and clinical evaluation documentation go via the Commission to the expert panel with neurological and neurostimulation competence. The panel issues a scientific opinion on the clinical evidence and benefit-risk conclusions.

The Notified Body gives due consideration to the panel's opinion, documents how the views were taken into account, and issues the certificate. Article 55 now runs in practice. The Notified Body notifies the competent authorities. The CEAR and the expert panel's opinion are transmitted so the authorities see both the clinical reasoning and the independent scientific view. The SSCP — the plain-language summary of the device's intended purpose, indications, contraindications, clinical evidence, benefit-risk, and residual risks — is published through Eudamed under Article 32.

From that moment, the file is no longer private. A clinician in another member state can read the SSCP. A competent authority can read the CEAR and the expert panel opinion. If a post-market signal emerges later, the reviewing authority already has the baseline the certificate rested on. Article 55 has turned a bilateral certification into a Union-level record.

Ship — Build a CER for scrutiny readiness

Scrutiny readiness is not a separate workstream. It is a set of disciplines baked into the clinical evaluation from the first draft.

Write the CER to be read by strangers. The reader is an expert panel member who reads the file once, a competent authority reviewer in another member state who reads it later, and a clinician who reads the SSCP. Every section must make sense without back-channel context.

Trace every clinical claim to specific evidence. Every benefit claimed, every risk controlled, every indication supported — each needs a traceable line to the clinical data and to the Annex I GSPR or risk management control it discharges. Narrative without traceability does not survive a close reading.

Make the benefit-risk conclusion earn its place. The benefit-risk section is what the expert panel will read most carefully. State the benefits quantitatively where evidence supports it, state residual risks clearly, and justify acceptability against the benefits. "The benefits outweigh the risks because the device is safe and effective" does not survive expert scrutiny.

Draft the SSCP alongside the CER, not after. The SSCP is a publication-grade document. If it is written as a last-minute extraction, it will show. Drafting in parallel surfaces CER gaps early, when they can still be fixed.

Document equivalence reasoning rigorously. If the clinical evaluation relies on equivalence under Article 61, the technical, biological, and clinical reasoning has to be explicit, traceable, and supported by sufficient access to the equivalent device's data.

Build the PMCF plan to close the gaps the CER leaves open. Every Class III clinical evaluation leaves open questions. The PMCF plan is where you show you know what they are and how you will answer them. Article 55 makes the PMCF plan visible through the SSCP and the wider file.

The common thread is subtractive discipline. Cut speculative sections. Cut evidence that does not bear on a specific GSPR or benefit-risk question. Cut narrative that restates the intended purpose in place of clinical argument. What remains is a CER that reads well to strangers — which is exactly what Article 55 requires.

Reality Check — Where do you stand on Article 55?

  1. Have you confirmed whether your device is in scope of Article 54 — and therefore of the Article 55 scrutiny mechanism — by reading the actual text of both Articles?
  2. Is your CER written to be read by an expert panel member who does not know your device, and by a competent authority reviewer in another member state?
  3. Is your SSCP drafted in parallel with the CER, or planned as a last-minute extraction?
  4. Does your benefit-risk analysis quantify benefits where evidence supports quantification, and justify residual risks explicitly?
  5. Does your project plan account for the Article 54 consultation time as a distinct block on the critical path?
  6. Have you confirmed with your Notified Body how they will handle the expert panel opinion documentation and how the CEAR and opinion will travel to competent authorities under Article 55?
  7. If the clinical evaluation relies on Article 61 equivalence, will the reasoning survive expert panel reading and cross-authority review?

Frequently Asked Questions

What is the MDR Article 55 scrutiny procedure? Article 55 of Regulation (EU) 2017/745 establishes a scrutiny mechanism for certain Class III implantable and Class IIb active devices. Where the Article 54 clinical evaluation consultation has been carried out, the Notified Body notifies the competent authorities of certificates issued in connection with that consultation, transmits the CEAR together with the expert panel's scientific opinion, and the summary of safety and clinical performance is made publicly available through Eudamed in accordance with Article 32.

Which devices are subject to Article 55 scrutiny? Article 55 operates in connection with the Article 54 consultation, which applies to certain implantable Class III devices (with the exceptions listed in Article 54) and to certain Class IIb active devices intended to administer or remove a medicinal product that Article 54 captures. The exact scope is set out in Article 54 of the Regulation.

Is Article 55 the same as Article 54? No. Article 54 establishes the clinical evaluation consultation procedure with an independent expert panel. Article 55 is the distinct scrutiny, notification, and publication mechanism that sits around the consultation — it handles the flow of the CEAR and expert panel opinion to competent authorities and the public availability of the SSCP through Eudamed.

Can the competent authorities or the expert panel overturn a certificate under Article 55? The Notified Body remains the decision-maker on certificate issuance. The expert panel's Article 54 opinion is not a veto — the Notified Body must give it due consideration and document how it was taken into account. Article 55 makes the certificate and opinion visible to competent authorities but does not vest veto power in them.

Where in the MDR is the scrutiny mechanism actually described? The scrutiny mechanism is in Article 55, read together with Article 54 (the consultation procedure), Annex IX Section 5.1 (the procedural steps), and Article 32 (the SSCP and its publication through Eudamed).

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 54 (clinical evaluation consultation procedure for certain Class III and Class IIb devices), Article 55 (mechanism for scrutiny of conformity assessments of certain Class III and Class IIb devices), Article 32 (summary of safety and clinical performance), Article 106 (expert panels), Annex IX Section 5.1 (procedure for the assessment of the clinical evaluation). Official Journal L 117, 5.5.2017.

This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. Article 55 is the reason a Class III implantable clinical evaluation file has to read well to strangers — because once the certificate issues, strangers are exactly who will read it.